search
Back to results

Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

Primary Purpose

ADHF

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Lung Doppler Signals
Sponsored by
Echosense Ltd.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for ADHF focused on measuring ADHF Dyspnea ED

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Patients with acute onset dyspnea (defined as shortness of breath (SOB) at rest or on exertion) and diagnostic uncertainty of etiology where heart failure is in consideration.
  • Patients designated to undergo chest X-ray as part of standard of care assessment.

Exclusion Criteria:

  • Obvious trauma contributing to dyspnea
  • Inability to provide written informed consent
  • Not speaking English or Spanish
  • Right-sided lobectomy
  • Patients with implanted ventricular assist device
  • Patient is unable to undergo the TPD test
  • Patient is already enrolled in a clinical study with experimental medications

Sites / Locations

  • Wayne State University
  • The university of Texas Southwestern Medical Center
  • Baylor College of Medicine

Outcomes

Primary Outcome Measures

Accuracy of diagnosis
overall accuracy of the TPD system for the determination of ADHF causing acute dyspnea in an ED setting versus the gold standard (GS) diagnosis as determined by the final adjudicated diagnosis

Secondary Outcome Measures

Sensitivity, Specificity, PPV, NPV of TPD diagnosis
Calculate the analysis success parameters

Full Information

First Posted
June 23, 2019
Last Updated
March 22, 2022
Sponsor
Echosense Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03998410
Brief Title
Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea
Official Title
Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Terminated
Why Stopped
due to the pandemic
Study Start Date
September 15, 2019 (Actual)
Primary Completion Date
July 1, 2021 (Actual)
Study Completion Date
December 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Echosense Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to evaluate Lung Doppler signals (LDS) among patients presenting to the emergency department with acute dyspnea, in order to determine the diagnostic value of this non-invasive method to discriminate ADHF causing dyspnea from any other cause i.e., non-ADHF causes of dyspnea.
Detailed Description
Dyspnea (shortness of breath) is a common symptom affecting as many as 25% of patients seen in ambulatory settings. It can be caused by many different underlying conditions, some of which arise acutely and can be life-threatening, making rapid clinical evaluation and targeted diagnostic studies of central importance. A number of disorders cause dyspnea, including acute decompensated heart failure (ADHF), chronic obstructive pulmonary disease (COPD), asthma, pulmonary embolism, pneumonia, metabolic acidosis, neuromuscular weakness, and others. The overlapping clinical presentations of these conditions and comorbid diseases can make the diagnostic evaluation of dyspnea a significant challenge. Acute heart failure (AHF) is a major cause of serious morbidity and death in the general population and one of the most common medical causes of hospitalization among people aged over 60. Patients presenting to the ED with ADHF must be evaluated and treated rapidly to ensure the best possible outcomes. The diagnosis should be made as soon as possible and therapy initiated. Delayed diagnosis at presentation may also result in patients being inappropriately transferred to non-specialist wards, resulting in longer stays, increased re-admission and poorer outcomes. The key to improving the time to diagnosis depends on the clinical evaluation alongside a readiness to initiate relevant additional tests. Previous studies showed that the TPD has the potential to differentiate between the cardiac cause of dyspnea and any other cause.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ADHF
Keywords
ADHF Dyspnea ED

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Recording Doppler US signals over the right wall chest
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Non-Randomized
Enrollment
130 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Lung Doppler Signals
Intervention Description
Recording Doppler ultrasound on the right chest wall
Primary Outcome Measure Information:
Title
Accuracy of diagnosis
Description
overall accuracy of the TPD system for the determination of ADHF causing acute dyspnea in an ED setting versus the gold standard (GS) diagnosis as determined by the final adjudicated diagnosis
Time Frame
Average of 1 year
Secondary Outcome Measure Information:
Title
Sensitivity, Specificity, PPV, NPV of TPD diagnosis
Description
Calculate the analysis success parameters
Time Frame
Average of 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Patients with acute onset dyspnea (defined as shortness of breath (SOB) at rest or on exertion) and diagnostic uncertainty of etiology where heart failure is in consideration. Patients designated to undergo chest X-ray as part of standard of care assessment. Exclusion Criteria: Obvious trauma contributing to dyspnea Inability to provide written informed consent Not speaking English or Spanish Right-sided lobectomy Patients with implanted ventricular assist device Patient is unable to undergo the TPD test Patient is already enrolled in a clinical study with experimental medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Judd Hollander, MD
Organizational Affiliation
judd.hollander@jefferson.edu
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wayne State University
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
The university of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea

We'll reach out to this number within 24 hrs